AP2013007085A0 - Bispecific binding molecules binding to VEGF and ANG2 - Google Patents
Bispecific binding molecules binding to VEGF and ANG2Info
- Publication number
- AP2013007085A0 AP2013007085A0 AP2013007085A AP2013007085A AP2013007085A0 AP 2013007085 A0 AP2013007085 A0 AP 2013007085A0 AP 2013007085 A AP2013007085 A AP 2013007085A AP 2013007085 A AP2013007085 A AP 2013007085A AP 2013007085 A0 AP2013007085 A0 AP 2013007085A0
- Authority
- AP
- ARIPO
- Prior art keywords
- binding
- ang2
- vegf
- bispecific
- binding molecules
- Prior art date
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 title 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 title 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160921 | 2011-04-01 | ||
| PCT/EP2012/055901 WO2012131078A1 (en) | 2011-04-01 | 2012-03-30 | Bispecific binding molecules binding to vegf and ang2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2013007085A0 true AP2013007085A0 (en) | 2013-08-31 |
Family
ID=45895502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2013007085A AP2013007085A0 (en) | 2011-04-01 | 2012-03-30 | Bispecific binding molecules binding to VEGF and ANG2 |
Country Status (36)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EA031182B1 (ru) * | 2012-03-30 | 2018-11-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ang2-связывающие молекулы |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| EA201500371A1 (ru) * | 2012-09-28 | 2015-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| TWI608015B (zh) * | 2015-01-16 | 2017-12-11 | 中央研究院 | 具有組織標的功能的抗發炎分子 |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| CA3255406A1 (en) | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| HUE051165T2 (hu) * | 2015-07-29 | 2021-03-01 | Allergan Inc | ANG-2 elleni, csak nehézláncot tartalmazó antitestek |
| WO2017030909A1 (en) * | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| CN116987187A (zh) * | 2015-09-23 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
| US11142569B2 (en) * | 2015-11-13 | 2021-10-12 | Ablynx N.V. | Serum albumin-binding immunoglobulin variable domains |
| AR106949A1 (es) | 2015-12-04 | 2018-03-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales |
| IL264962B2 (en) * | 2016-08-23 | 2024-09-01 | Medimmune Ltd | Antibodies against VEGF-A and against ANG2 and their uses |
| CA3034576A1 (en) | 2016-08-23 | 2018-03-01 | Medimmune Limited | Anti-vegf-a antibodies and uses thereof |
| BR112019012062A2 (pt) * | 2016-12-14 | 2019-11-12 | Progenity Inc | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos |
| RU2648164C1 (ru) * | 2016-12-19 | 2018-03-22 | Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| WO2018128939A1 (en) | 2017-01-05 | 2018-07-12 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| KR102717656B1 (ko) | 2017-05-31 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 |
| BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| JP7005772B2 (ja) | 2018-02-06 | 2022-02-10 | エフ．ホフマン－ラ ロシュ アーゲー | 眼科疾患の処置 |
| US12171764B2 (en) * | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| US11001635B2 (en) | 2018-06-29 | 2021-05-11 | Gensun Biopharma Inc. | Antitumor antagonists |
| IL281717B2 (en) | 2018-10-29 | 2025-07-01 | Hoffmann La Roche | Antibody formulation |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
| US12428480B2 (en) | 2019-12-11 | 2025-09-30 | Cullinan Therapeutics, Inc. | Anti-CD19 antibodies and multi-specific binding proteins |
| WO2021119531A1 (en) * | 2019-12-11 | 2021-06-17 | Cullinan Management, Inc. | Anti-serum albumin antibodies |
| WO2021155151A1 (en) * | 2020-01-29 | 2021-08-05 | The Methodist Hospital System | Multivalent ligands targeting cell surface receptors and force measurement platform for making the same |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| CN116234822A (zh) | 2020-07-07 | 2023-06-06 | 治纳辅医药科技有限公司 | 一种包括补体途径抑制剂和血管生成抑制剂的融合蛋白及其用途 |
| JP2023550591A (ja) | 2020-11-02 | 2023-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
| MX2023009392A (es) * | 2021-02-10 | 2023-11-09 | Shanghai Jemincare Pharmaceuticals Co Ltd | Anticuerpo anti-vegf y uso del mismo. |
| WO2022231930A1 (en) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| CN117500828A (zh) * | 2021-06-04 | 2024-02-02 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| WO2023016516A1 (zh) * | 2021-08-13 | 2023-02-16 | 信达生物制药(苏州)有限公司 | 抗vegf a和vegf c双特异性抗体及其用途 |
| KR20240048555A (ko) * | 2021-09-10 | 2024-04-15 | 소테르 바이오파마 피티이. 리미티드 | 항 ang2 항체 및 그 제조방법과 응용 |
| CU24770B1 (es) * | 2021-12-15 | 2025-09-01 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| EP4582447A1 (en) | 2022-09-14 | 2025-07-09 | Quaerite Biopharm Research (Beijing) Co., Ltd. | Anti-vegfa antibody or antigen-binding fragment thereof and use thereof |
| CN119790077A (zh) | 2022-09-14 | 2025-04-08 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
| AU2023404729A1 (en) * | 2022-12-01 | 2025-06-26 | Innovent Biologics (Suzhou) Co., Ltd. | Trispecific fusion protein and use thereof |
| TW202426052A (zh) * | 2022-12-01 | 2024-07-01 | 大陸商信達生物製藥（蘇州）有限公司 | 包含結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子的製劑以及其用途 |
| WO2024178730A1 (zh) * | 2023-03-02 | 2024-09-06 | 清华大学 | 用于抑制脉络膜新生血管的玻璃体内抗vegf可结晶蛋白药物 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2025219504A1 (en) | 2024-04-19 | 2025-10-23 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| US5408535A (en) | 1993-09-07 | 1995-04-18 | Miles Inc. | Video test strip reader and method for evaluating test strips |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2005518805A (ja) | 2002-03-01 | 2005-06-30 | ボール・ホーティカルチャラル・カンパニー | 花組織においてトランスジーンを発現させるためのｌｉｓプロモーター |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| EP1537145A1 (en) | 2002-09-10 | 2005-06-08 | Lorantis Limited | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20050043220A1 (en) | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
| US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| SI1660057T1 (sl) | 2003-08-27 | 2012-10-30 | Ophthotech Corp | Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| JP5113523B2 (ja) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| MX2007007165A (es) | 2004-12-17 | 2007-08-14 | Genentech Inc | Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior. |
| KR101017301B1 (ko) | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
| EP2949668B1 (en) * | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| BRPI0609797B8 (pt) | 2005-05-20 | 2021-05-25 | Ablynx Nv | nanocorpos melhorados para o tratamento de desordens mediadas por agregação |
| AU2006309284B2 (en) | 2005-05-31 | 2012-08-02 | Board Of Regents, The University Of Texas System | Methods and compositions related to determination and use of white blood cell counts |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1928486A2 (en) | 2005-09-01 | 2008-06-11 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| CN101305426A (zh) | 2005-09-30 | 2008-11-12 | 富士通株式会社 | 信息存储装置 |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| AU2007209202A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US7570881B2 (en) | 2006-02-21 | 2009-08-04 | Nokia Corporation | Color balanced camera with a flash light unit |
| US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2654304A1 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| CN101500605B (zh) | 2006-08-07 | 2014-04-30 | 瑞泽恩制药公司 | Dll4拮抗剂在治疗局部缺血性损伤中的用途 |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2086998B1 (en) | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| MX2009004027A (es) | 2006-10-20 | 2009-09-28 | Schering Corp | Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso. |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| US20110118185A9 (en) | 2007-02-21 | 2011-05-19 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| EA200901301A1 (ru) | 2007-06-06 | 2010-06-30 | Домантис Лимитед | Полипептиды, вариабельные домены антител и антагонисты |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| WO2009055343A2 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| JP5608091B2 (ja) | 2007-11-26 | 2014-10-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 抗メソセリン抗体およびその使用 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| MY166445A (en) | 2008-03-18 | 2018-06-27 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use |
| CA2720763A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| LT2285408T (lt) | 2008-06-05 | 2019-01-25 | Ablynx N.V. | Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui |
| KR102095257B1 (ko) | 2008-06-25 | 2020-04-01 | 노바르티스 아게 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| WO2010027981A1 (en) | 2008-09-03 | 2010-03-11 | Genentech, Inc. | Multispecific antibodies |
| AU2009294415B2 (en) | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2746395C (en) | 2008-12-10 | 2019-07-09 | Ablynx N.V. | Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| CN104374932A (zh) | 2009-01-13 | 2015-02-25 | Fio公司 | 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备 |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| BRPI1012321A8 (pt) | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | Anticorpos anti-vegf e seus usos |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| UY32917A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| MX2012009554A (es) | 2010-02-23 | 2012-11-23 | Hoffmann La Roche | Terapia anti-angiogenesis para el tratamiento del cancer ovarico. |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2012012499A1 (en) | 2010-07-20 | 2012-01-26 | Nurx Pharmaceuticals, Inc. | Optical reader system |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| WO2012061374A2 (en) | 2010-11-02 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| BR112013029713A2 (pt) | 2011-05-27 | 2016-09-06 | Novartis Ag | método de tratamento de distúrbios da visão |
| DK3485903T5 (da) | 2011-09-23 | 2024-09-02 | Mereo Biopharma 5 Inc | Vegf/dll4-bindende midler og anvendelser deraf |
| EA031182B1 (ru) * | 2012-03-30 | 2018-11-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ang2-связывающие молекулы |
| US9292583B2 (en) * | 2012-11-27 | 2016-03-22 | Google Inc. | Method of displaying search results |
-
2012
- 2012-03-29 US US13/433,359 patent/US9527925B2/en active Active
- 2012-03-30 PH PH1/2013/502044A patent/PH12013502044A1/en unknown
- 2012-03-30 EA EA201600338A patent/EA036746B1/ru not_active IP Right Cessation
- 2012-03-30 ES ES12711201.9T patent/ES2606302T3/es active Active
- 2012-03-30 KR KR1020137028120A patent/KR101907572B1/ko active Active
- 2012-03-30 UA UAA201312685A patent/UA114707C2/uk unknown
- 2012-03-30 MX MX2016000726A patent/MX343440B/es unknown
- 2012-03-30 AU AU2012237234A patent/AU2012237234B2/en not_active Ceased
- 2012-03-30 SG SG10201602373TA patent/SG10201602373TA/en unknown
- 2012-03-30 SG SG2013070842A patent/SG193561A1/en unknown
- 2012-03-30 UY UY0001033998A patent/UY33998A/es unknown
- 2012-03-30 EP EP12711201.9A patent/EP2694546B1/en active Active
- 2012-03-30 CN CN201610173463.7A patent/CN105820243A/zh active Pending
- 2012-03-30 LT LTEP12711201.9T patent/LT2694546T/lt unknown
- 2012-03-30 CN CN201280026064.8A patent/CN103562222B/zh active Active
- 2012-03-30 PL PL12711201T patent/PL2694546T3/pl unknown
- 2012-03-30 PT PT127112019T patent/PT2694546T/pt unknown
- 2012-03-30 AP AP2013007085A patent/AP2013007085A0/xx unknown
- 2012-03-30 DK DK12711201.9T patent/DK2694546T3/en active
- 2012-03-30 WO PCT/EP2012/055901 patent/WO2012131078A1/en not_active Ceased
- 2012-03-30 EP EP16189545.3A patent/EP3144322A3/en not_active Withdrawn
- 2012-03-30 JP JP2014501665A patent/JP6023786B2/ja active Active
- 2012-03-30 CA CA2827817A patent/CA2827817C/en active Active
- 2012-03-30 EA EA201301108A patent/EA025148B1/ru not_active IP Right Cessation
- 2012-03-30 BR BR112013025304-5A patent/BR112013025304B1/pt active IP Right Grant
- 2012-03-30 RS RS20161083A patent/RS55361B1/sr unknown
- 2012-03-30 MA MA36274A patent/MA34979B1/fr unknown
- 2012-03-30 HU HUE12711201A patent/HUE030148T2/en unknown
- 2012-03-30 HR HRP20161689TT patent/HRP20161689T1/hr unknown
- 2012-03-30 AR ARP120101130A patent/AR085984A1/es active IP Right Grant
- 2012-03-30 MY MYPI2013003467A patent/MY171007A/en unknown
- 2012-03-30 SI SI201230813A patent/SI2694546T1/sl unknown
- 2012-03-30 MX MX2013010949A patent/MX337543B/es active IP Right Grant
- 2012-03-30 PE PE2013002134A patent/PE20140448A1/es active IP Right Grant
-
2013
- 2013-08-13 IL IL227936A patent/IL227936B/en active IP Right Grant
- 2013-09-12 CL CL2013002623A patent/CL2013002623A1/es unknown
- 2013-09-26 TN TNP2013000390A patent/TN2013000390A1/fr unknown
- 2013-09-27 CO CO13230713A patent/CO6801639A2/es active IP Right Grant
- 2013-10-28 EC ECSP13013001 patent/ECSP13013001A/es unknown
-
2014
- 2014-04-10 HK HK16113827.4A patent/HK1225400A1/zh unknown
-
2016
- 2016-10-07 JP JP2016198857A patent/JP6297657B2/ja active Active
- 2016-11-14 US US15/350,364 patent/US10414828B2/en active Active
- 2016-12-13 CY CY20161101286T patent/CY1118339T1/el unknown
-
2017
- 2017-01-13 AU AU2017200237A patent/AU2017200237B2/en not_active Ceased
-
2019
- 2019-07-18 US US16/515,231 patent/US11161916B2/en active Active
-
2021
- 2021-09-27 US US17/485,561 patent/US20220017642A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227936B (en) | Bispecific binding molecules that bind to vegf and 2ang | |
| IL270223B (en) | Molecules that specifically bind tdp–43 | |
| IL268336B (en) | il-18 binding molecules | |
| IL230553B (en) | Bispecific antigen binding molecules | |
| EP2762569A4 (en) | NGF APTAMER AND APPLICATION THEREOF | |
| LT2604625T (lt) | Surišančių molekulių generavimas | |
| AP2013007086A0 (en) | Bispecific binding molecules binding to DII4 and Ang2 | |
| EP2723379A4 (en) | ANTI-ALPHA-SYNUCLEIN BINDING MOLECULES | |
| EP2705425A4 (en) | BINDING APPLICATIONS TO DEVICE CAPACITIES | |
| IL232726B (en) | Her3-specific binding molecules and their uses | |
| GB201104542D0 (en) | Content provision | |
| IL235134B (en) | il–6 binding molecules | |
| ZA201409540B (en) | Binding molecules targeting pathogens |